Prime Medicine operates as a biotechnology company that delivers the promise of gene editing using Prime Editing.
Prime Medicine is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly "search and replace" to restore normal genetic function and address the fundamental causes of disease.It was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 20, 2022 | IPO | $175M | — | — | — | Detail |
Jul 13, 2021 | Series B | $200M | 12 | — | — | Detail |
Oct 22, 2019 | Series A | $115M | 5 | ARCH Venture Partners F-Prime Capital GV | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | — | Series B |
Arrive | — | Series B |
Casdin Capital | — | Series B |
Cormorant Asset Management | — | Series B |
F-Prime Capital | — | Series B |
GV | — | Series B |
Moore Strategic Ventures | — | Series B |
Newpath Management | — | Series B |
PSP Investments | — | Series B |
Redmile Group | — | Series B |